Billings Gazette

Share

Billings Gazette

 •  November 29, 2017

Big pharma stocks have been longtime favorites among investors for several reasons. The fact that they're big means that that they generate huge cash flow, which typically translates to attractive dividends. And big pharma companies operate in a growing industry, with demand for prescription drugs continuing to rise -- especially with expanding...

Billings Gazette

 •  August 23, 2017

Two members of the U.S. House of Representatives Committee on Oversight and Government Reform want to know why the prices of multiple sclerosis (MS) drugs are so high. Rep. Elijah Cummings (D-Md.) and Rep. Peter Welch (D-Vt.) have sent letters to seven drugmakers, including Biogen (NASDAQ: BIIB) and Teva Pharmaceutical Industries (NYSE: TEVA),...

Billings Gazette

 •  August 22, 2017

Progress marches on in the fight against cancer. While more biosimilars are becoming available for top cancer drugs of the past, biopharmaceutical companies are developing newer and more powerful treatments. Market research firm EvaluatePharma evaluated all of the experimental cancer drugs in late-stage development. The firm ranked these drugs by...

Billings Gazette

 •  August 6, 2017

If you've picked up a prescription from your local pharmacy recently, you probably don't need me to tell you that prescription drug prices have handily outpaced wage growth and the rate of inflation in the U.S. for some time now. Cancer drug prices are headed into the stratosphere According to Segal Consulting, prescription drugs are estimated to...

Billings Gazette

 •  July 23, 2017

You don't have to be Nostradamus to successfully predict that more states will legalize marijuana -- whether for medicinal use only or for recreational use. A bandwagon effect seems quite likely, considering 29 states plus the District of Columbia have already legalized medical marijuana. Nine of those (including D.C.) have also made recreational...

Billings Gazette

 •  July 21, 2017

A new gene therapy drug, the first in its class, was recommended for approval to the US Food and Drug Administration by an advisory committee on Wednesday. If approved by the FDA, the agency would consider it the first gene therapy to hit the market. The drug may provide a second chance to some leukemia patients whose first-line drugs have...

Billings Gazette

 •  July 16, 2017

Corcept Therapeutics (NASDAQ: CORT) is one hot biotech stock no matter how you look at it. Shares have nearly quintupled in value in just three years. So far in 2017, Corcept stock is up around 70%. Those kinds of returns could make millionaires out of some investors if the momentum continues. But is it too late to buy Corcept stock now? Here are...

Billings Gazette

 •  June 25, 2017

The U.S. Food and Drug Administration (FDA) is tasked with an inglorious job. It digs through hundreds, if not thousands, of pages of clinical trial data to determine if an experimental drug or medical device effectively reaches its treatment goal without outweighing the risks involved with taking or using it. The FDA has formally done this task...